Arovella Therapeutics Ltd (ALA) — Cash Flow-to-Debt Ratio
Arovella Therapeutics Ltd (ALA) has a Cash Flow-to-Debt Ratio of -1.28x as of December 2025, meaning its operating cash flow of AU$-1.71 Million could theoretically repay -1% of its total liabilities (AU$1.33 Million) in one year. See ALA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arovella Therapeutics Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Arovella Therapeutics Ltd across 13 annual periods. Also explore how fast is Arovella Therapeutics Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Arovella Therapeutics Ltd (2013–2025)
Year-by-year debt coverage analysis for Arovella Therapeutics Ltd. For market capitalisation and broader financial context, see ALA market cap.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.55x | AU$-6.93 Million | AU$1.52 Million | ▼ -35.2% |
| 2024 | -3.36x | AU$-6.91 Million | AU$2.06 Million | ▲ +11.2% |
| 2023 | -3.78x | AU$-6.40 Million | AU$1.69 Million | ▲ +3.7% |
| 2022 | -3.93x | AU$-6.27 Million | AU$1.60 Million | ▼ -89.1% |
| 2021 | -2.08x | AU$-3.54 Million | AU$1.71 Million | ▼ -85.4% |
| 2020 | -1.12x | AU$-2.88 Million | AU$2.57 Million | ▼ -2.2% |
| 2019 | -1.10x | AU$-2.50 Million | AU$2.28 Million | ▼ -122.8% |
| 2018 | -0.49x | AU$-2.55 Million | AU$5.18 Million | ▼ -82.2% |
| 2017 | -0.27x | AU$-854.22K | AU$3.16 Million | ▲ +56.4% |
| 2016 | -0.62x | AU$-1.80 Million | AU$2.91 Million | ▲ +30.9% |
| 2015 | -0.90x | AU$-3.15 Million | AU$3.52 Million | ▼ -49.3% |
| 2014 | -0.60x | AU$-2.61 Million | AU$4.36 Million | ▼ -50.7% |
| 2013 | -0.40x | AU$-1.61 Million | AU$4.04 Million | — |